Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Maternus-Kliniken AG (MAK.DE)
Berlin, DE
Maternus-Kliniken AG oversees a network of facilities that includes retirement and nursing residences, rehabilitation centers, and a variety of specialized service companies. This enterprise primarily focuses on delivering geriatric care and medical rehabilitation services. Furthermore, it offers an extensive range of support options, such as emergency response systems, assisted living arrangements, and various care modalities including home care, residential care, temporary stays, and care for individuals with disabilities. Its services also encompass comprehensive rehabilitation and post-treatment programs. The company maintains roughly 23 establishments throughout Germany. Founded in 1877, Maternus-Kliniken AG's corporate headquarters are situated in Berlin, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.06% | -0.98% | -6.48% | +6.32% | -2.88% | +2.54% | -35.26% | -39.88% | -74.62% | -39.52% | -89.66% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+3.5% Q4'25: +13.8% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%-4.8% Q4'25: -133.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-3.1% Q4'25: +3.8% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%-3.1% Q4'25: -14.6% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%—
-
Share dilution Medical - Care Facilities: +0.0%0.0% ★ Q4'25: -0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×— Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
106.22M
est.
|
106.41M
est: 108.13M (-1.6%)
|
109.81M
est: 110.53M (-0.7%)
|
112.80M
est: 114.69M (-1.7%)
|
111.81M
est: 114.59M (-2.4%)
|
110.90M
est: 112.36M (-1.3%)
|
113.94M
est: 115.30M (-1.2%)
|
113.57M
est: 113.88M (-0.3%)
|
122.04M
est: 123.32M (-1.0%)
|
123.27M
est: 125.15M (-1.5%)
|
124.04M
est: 123.90M (+0.1%)
|
127.14M
est: 128.80M (-1.3%)
|
| EBITDA |
8.62M
est.
|
9.05M
est: 8.60M (+5.2%)
|
10.99M
est: 8.80M (+24.9%)
|
11.00M
est: 9.13M (+20.5%)
|
10.97M
est: 9.12M (+20.3%)
|
8.96M
est: 8.94M (+0.2%)
|
2.94M
est: 9.18M (-67.9%)
|
2.17M
est: 9.06M (-76.0%)
|
37.99M
est: 9.81M (+287.1%)
|
13.43M
est: 9.96M (+34.8%)
|
11.04M
est: 3.07M (+259.7%)
|
11.38M
est: 10.46M (+8.8%)
|
| EBIT |
-2.21M
est.
|
2.14M
est: -2.20M (+197.1%)
|
4.24M
est: -2.25M (+288.4%)
|
6.24M
est: -2.33M (+367.2%)
|
6.18M
est: -2.33M (+365.0%)
|
3.89M
est: -2.29M (+270.1%)
|
1.84M
est: -2.35M (+178.3%)
|
-6.19M
est: -2.32M (-166.9%)
|
32.01M
est: -2.51M (+1,375.0%)
|
8.06M
est: -2.55M (+416.2%)
|
5.84M
est: 8.48M (-31.1%)
|
6.38M
est: -2.67M (+338.4%)
|
| Net Income |
-2.12M
est.
|
-4.28M
est: -5.53M (+22.7%)
|
-2.74M
est: -4.68M (+41.4%)
|
886.0K
|
1.98M
est: 638.5K (+209.9%)
|
-1.89M
est: -2.55M (+26.1%)
|
-8.60M
est: -2.55M (-236.7%)
|
-12.73M
est: -5.32M (-139.1%)
|
26.84M
est: -212.8K (+12,712.0%)
|
2.36M
est: -1.49M (+258.3%)
|
1.10M
est: 2.47M (-55.4%)
|
-1.46M
|
| SGA |
3.24M
est.
|
—
est: 3.23M (-100.0%)
|
—
est: 3.30M (-100.0%)
|
—
est: 3.43M (-100.0%)
|
—
est: 3.42M (-100.0%)
|
—
est: 3.36M (-100.0%)
|
5.67M
est: 3.44M (+64.6%)
|
5.78M
est: 3.40M (+69.8%)
|
4.80M
est: 3.68M (+30.2%)
|
5.02M
est: 3.74M (+34.3%)
|
4.16M
est: 72.30M (-94.2%)
|
4.27M
est: 3.92M (+8.8%)
|
| EPS |
-0.10
est.
|
-0.20
est: -0.26 (+23.8%)
|
-0.13
est: -0.22 (+41.5%)
|
0.04
|
0.08
est: 0.03 (+164.0%)
|
-0.09
est: -0.12 (+25.7%)
|
-0.41
est: -0.12 (-238.3%)
|
-0.61
est: -0.25 (-141.6%)
|
1.28
est: -0.01 (+12,773.3%)
|
0.11
est: -0.07 (+255.6%)
|
0.05
|
-0.07
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mario Augusto Ruano Wohlers | Member of Board of Management | 5.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MAK.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
